Assessment of Guselkumab (Tremfya) and IL-17 Inhibitor Therapies in Patients With Psoriatic Arthritis in Routine Clinical Practice; A Prospective, Observational Cohort Study
Latest Information Update: 23 Jul 2024
At a glance
- Drugs Guselkumab (Primary) ; Interleukin 17 inhibitors
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms PsABIOnd
- Sponsors Janssen Pharmaceutica
- 17 Jul 2024 Planned End Date changed from 6 Dec 2027 to 1 Aug 2027.
- 17 Jul 2024 Planned primary completion date changed from 6 Dec 2027 to 1 Aug 2027.
- 18 Jun 2024 Planned End Date changed from 7 Dec 2027 to 6 Dec 2027.